Tweet
Mistaken information. please delete
-
Last edited by Aniki; 11-19-2013, 08:19 AM. -
Hi Aniki,
We are committed to providing our 454 instruments, parts, reagents, consumables, service and support for all our 454 products currently on the market over the next three years until mid-2016. We will also be offering new updates, including longer reads for the GS Junior System (both random fragment and amplicon libraries),
If you have any specific questions or concerns I encourage you to reach out to your local Roche service representative.
Best Regards,
Nicole
Senior Support Specialist
454 Life Sciences, A Roche Company -
Dear Nicole,
my apologies, I was given information that Roche will no longer support the 454. Please accept my sincerest apology for the confusion.Comment
-
The first FDA-approved CRISPR-based therapy marked the transition of therapeutic gene editing from a dream to reality1. CRISPR technologies have streamlined gene editing, and CRISPR screens have become an important approach for identifying genes involved in disease processes2. This technique introduces targeted mutations across numerous genes, enabling large-scale identification of gene functions, interactions, and pathways3. Identifying the full range...08-27-2024, 04:44 AM -
Sequencing mRNA provides a snapshot of cellular activity, allowing researchers to study the dynamics of cellular processes, compare gene expression across different tissue types, and gain insights into the mechanisms of complex diseases. “mRNA’s central role in the dogma of molecular biology makes it a logical and relevant focus for transcriptomic studies,” stated Sebastian Aguilar Pierlé, Ph.D., Application Development Lead at Inorevia. “One of the major hurdles for...08-07-2024, 12:11 PM
Comment